Studies have shown that the levels of low-density lipoprotein, cholesterol and triglycerides in patients with chronic myeloid leukemia treated with ponatinib for 3 months are significantly increased (Caocci et al., 2020), and the use of l-asparaginase in the treatment of ALL is also associated with severe hyperlipidemia (Bhojwani et al., 2014). This evidence concerns the gene ASPG and hyperlipidemia.